A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
Status:
Completed
Trial end date:
2018-06-17
Target enrollment:
Participant gender:
Summary
This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the
pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children,
less than (<) 13 years of age, with confirmed influenza infection. Participants will be
randomized to receive either the standard dose or triple dose of oseltamivir orally daily for
a minimum of 5 days and up to 20 days. Infants <1 year of age will be randomized to the
standard dose arm only.